Cargando…

Epigenetic silencing of long non-coding RNA BM742401 in multiple myeloma: impact on prognosis and myeloma dissemination

BACKGROUND: Long non-coding RNA (lncRNA) BM742401 is a tumor suppressor in gastric cancer and chronic lymphocytic leukemia. As the promoter and coding region of BM742401 are fully embedded in a CpG island, we hypothesized that BM742401 is a tumor suppressor lncRNA epigenetically silenced by promoter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Zhenhai, Kumar, Shaji, Jin, Dong-Yan, Calin, George A., Chng, Wee-Joo, Siu, Kam-Leung, Poon, Ming-Wai, Chim, Chor Sang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Primary Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7446116/ https://www.ncbi.nlm.nih.gov/pubmed/32855620 http://dx.doi.org/10.1186/s12935-020-01504-4

Ejemplares similares

Epigenetic silencing of tumor suppressor long non-coding RNA BM742401 in chronic lymphocytic leukemia
por: Wang, Lu Qian, et al.
Publicado: (2016)

Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact
por: Li, Zhenhai, et al.
Publicado: (2019)

Epigenetic silencing of LPP/miR-28 in multiple myeloma
por: Li, Zhenhai, et al.
Publicado: (2018)

Epigenetic silencing of a long non-coding RNA KIAA0495 in multiple myeloma
por: Wong, Kwan Yeung, et al.
Publicado: (2015)

Establishment of a bortezomib-resistant Chinese human multiple myeloma cell line: MMLAL
por: Wong, Kwan Yeung, et al.
Publicado: (2013)

A known expressed sequence tag, BM742401, is a potent lincRNA inhibiting cancer metastasis
por: Park, Seong-Min, et al.
Publicado: (2013)

Distinct promoter methylation profile reveals spatial epigenetic heterogeneity in 2 myeloma patients with multifocal extramedullary relapses
por: Yao, Qiumei, et al.
Publicado: (2018)

Survival of >20 years in a myeloma patient with an unusual combination of t(14;16) and hyperdiploidy: A case report
por: CHIM, CHOR SANG, et al.
Publicado: (2013)

Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma: A Comparison With Real-Time Quantitative PCR
por: Yao, Qiumei, et al.
Publicado: (2021)

Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma
por: Wong, Kwan Yeung, et al.
Publicado: (2018)

Immunotherapy in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2020)

Skin dissemination of myeloma
por: Męcińska-Jundziłł, Kaja, et al.
Publicado: (2017)

Metabolic Vulnerabilities in Multiple Myeloma
por: Lim, Julia S. L., et al.
Publicado: (2022)

MMSET: Role and Therapeutic Opportunities in Multiple Myeloma
por: Xie, Zhigang, et al.
Publicado: (2014)

Case series: MRD negativity assessment using (11)C-Acetate PET with 3-weekly daratumumab-based quadruplet induction in newly diagnosed multiple myeloma
por: Ngai, Cheong, et al.
Publicado: (2021)

Epigenetic silencing of miR-342-3p in B cell lymphoma and its impact on autophagy
por: Zhang, Min Yue, et al.
Publicado: (2020)

Relationship between abnormal osteoblasts and cellular immunity in multiple myeloma
por: Fu, Rong, et al.
Publicado: (2014)

Updated survivals and prognostic factor analysis in myeloma treated by a staged approach use of bortezomib/thalidomide/dexamethasone in transplant eligible patients
por: Chim, Chor Sang
Publicado: (2010)

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma
por: Yao, Qiumei, et al.
Publicado: (2019)

MicroRNA: Important Player in the Pathobiology of Multiple Myeloma
por: Bi, Chonglei, et al.
Publicado: (2014)

Implications of Heterogeneity in Multiple Myeloma
por: de Mel, Sanjay, et al.
Publicado: (2014)

Cyproheptadine, an epigenetic modifier, exhibits anti-tumor activity by reversing the epigenetic silencing of IRF6 in urothelial carcinoma
por: Jou, Yeong-Chin, et al.
Publicado: (2021)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)—a trial by the Asian Myeloma Network
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2019)

Osteoblast inhibition by chemokine cytokine ligand3 in myeloma-induced bone disease
por: Fu, Rong, et al.
Publicado: (2014)

Alteration of metabolite profiling by cold atmospheric plasma treatment in human myeloma cells
por: Xu, Dehui, et al.
Publicado: (2018)

Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes
por: Went, Molly, et al.
Publicado: (2019)

CAR T-cell therapy in multiple myeloma: more room for improvement
por: Teoh, Phaik Ju, et al.
Publicado: (2021)

Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report
por: Murray, David L., et al.
Publicado: (2021)

Arsenic trioxide inhibits the proliferation of myeloma cell line through notch signaling pathway
por: Hu, Jiasheng, et al.
Publicado: (2013)

Identification of key biomarkers associated with cell adhesion in multiple myeloma by integrated bioinformatics analysis
por: Peng, Yue, et al.
Publicado: (2020)

Epigenetic Silencing of Tumor Suppressor lncRNA NKILA: Implication on NF-κB Signaling in Non-Hodgkin’s Lymphoma
por: Zhang, Min-Yue, et al.
Publicado: (2022)

Biological Hallmarks and Emerging Strategies to Target STAT3 Signaling in Multiple Myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2022)

Protein kinase ERK contributes to differential responsiveness of human myeloma cell lines to IFNα
por: Song, Lun, et al.
Publicado: (2002)

Potential Clinical Application of Genomics in Multiple Myeloma
por: Soekojo, Cinnie Yentia, et al.
Publicado: (2018)

Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN)
por: Liu, Jin, et al.
Publicado: (2020)

Epigenetic Aberrations in Multiple Myeloma
por: Caprio, Cinzia, et al.
Publicado: (2020)

Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study
por: Gupta, Neeraj, et al.
Publicado: (2015)

STAT3: A Promising Therapeutic Target in Multiple Myeloma
por: Chong, Phyllis S. Y., et al.
Publicado: (2019)

Exosomal circRNA as a novel potential therapeutic target for multiple myeloma-related myocardial damage
por: Sun, Runjie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_csmle0f2sr5d07o6u8dr5q19nj